Q: What is the prevalence, the genetic predisposition, and what are the clinical consequences of reduced LVEF and/or RVEF among endurance athletes?

A: Approximately 1 in 6 had reduced LVEF and/or RVEF

Read more: bit.ly/4bu483E #SportsCardio

📢 📆 Faltan 10 días para que comience la Campaña Conocé y Controlá tu Presión Arterial 2024!

💜Si sos hipertenso (o no sabés si lo sos) o si tenés algún hipertenso en tu familia, estate atento a las redes sociales💜

~ThIs WeEk~
Join Francisco Rios for a #HypHIP Chat with Yashashwi Pokharel (he/his/him) Sameer Acharya Justin B. Moore, PhD, MS, FACSM Hayden Bosworth on May 8 15:00-16:00UTC

Self-Measured Blood Pressure Guided Pharmacotherapy:A Systematic Review & Meta-analysis of US-based Telemedicine Trials ahajrnls.org/3OSuhQu

Informative statement on orthostatic hypertension.
journals.lww.com/jhypertension/…

Full article: Guidelines-based therapeutic strategies for controlling hypertension in non-controlled hypertensive patients followed by family physicians in primary health care in Portugal: the GPHT-PT study tandfonline.com/doi/full/10.10…

Multiple drug intolerance in antihypertensive patients: what... : Journal of Hypertension journals.lww.com/jhypertension/…

Get involved in MMM 2024!

Check out the MMM website and access resources for MMM and World Hypertension Day on the ISH website:
ish-world.com/world-hyperten…

#MMM2024 #TheBigSqueeze #hypertension #bloodpressure

Such a lovely surprise arrived 🙏

Honoured & grateful to contribute with co-authors Erin D. Michos, M.D. Anum Minhas

We extend the date for abstract submission until May 20, 2024.
Don't miss the opportunity to submit your abstract for ISH 2024!
-------------------
Ampliamos la fecha de envío de trabajos hasta el 20 de mayo de 2024.
¡No pierda la oportunidad de enviar su resúmen para ISH 2024!

👉Targeting Lp(a): Can RNA Therapeutics Provide the Next Step in the Prevention of CVD?

☝️Modulation of apo(a) expression via LPA transcripts represents a promising target for RNA-based therapies, with numerous publications reporting on their beneficial effects in reducing Lp(a)…

Therapeutic inertia with initial low dose quadruple combination therapy for hypertension: results from the QUARTET trial Amy Von Huben simone Marschner Prof Gemma Figtree AM Clara Chow Emily Atkins Prof Markus Schlaich

ahajrnls.org/3UrsaoY

Más beneficio de semaglutida.
Los resultados del #Flow que se presentará el 24/05.
Pacientes con enfermedad renal diabetes:
-⬇️ progresión Enf.renal
-⬇️ eventos cardiovasculares
-⬇️ mortalidad total

Y lo siguen llamando “un fármaco para adelgazar” …
Es decepcionante

ICYMI - #hypertension publication alert🚨

🔍Our The Cochrane Library review on evening vs morning dosing considers evidence from 25 studies that randomised more than 3,000 people:
tiny.cc/pm-am-htn

#SystematicReview #prescribing #HighBloodPressure

There is a ceiling effect of BP lowering treatment benefits (nadir 125/75mmHg) with a higher residual risk in secondary prevention. 'The earlier, the better' prevails over 'the lower, the better' Dimitrios Farmakis

ahajrnls.org/4aYGgoT

🆕 Hipertensión maligna: Una enfermedad cardiovascular sistémica.

📕 JACC
📁 cardioteca.com/hipertension-a…

📢Les compartimos el artículo SAHA de Abril 2024 a cargo de la Dra. Susana Lupi

Link💻: saha.org.ar/Art%C3%ADculo_…

SABOURETCardiologist Maciej Banach Federica Fogacci Arrigo F.G. Cicero Pr D ANGOULVANT Seba GZ, MD, MSc Marco Bernardi Luigi Spadafora Giuseppe Biondi-Zoccai Italo Kumamoto MIЯVΛƬ #IC Poonam Velagapudi Marcelo Nakazone Djenane Nakhle, PhD Dr Monica Nafria Anu Lala-Trindade Jimmy Turner Seth Trueger Nicolas Renna, MD PhD ISHF FESC Pradeep Natarajan Bartosz Hudzik MD PhD FESC FACC LipoFan John P Erwin III MD MBA FACC Fabricio Gaston Procopio Prof Kausik Ray FMedSci Larry Aldama María J. Díaz Candamio Javier Escalada #Yoelijoendocrino Dr. Pedro Yeverino S Francisco Dias Cláudio Matt DiMeglio DO, MBA “Food is Medicine” ❤️ #Prevention
acc.org/Latest-in-Card…

📢Les compartimos la controversia SAHA de Abril 2024 a cargo de los Dres. Julian Minetto y Gustavo Cerri.

Link💻: saha.org.ar/Controversia_a…

Participando del Investigator Meeting del estudio ARTEMIS IM con ziltivekimab en Chicago-USA

📢 We are excited to announce the Scientific Programme for our 2024 Meeting in #Cartagena #Colombia , 19-22 September.

Find out more about our innovative programme that addresses current and future challenges in #hypertension :

🔗ish2024.org/scientific-pro…

ISH 2024